Killing effect of 131I-Herceptin on breast cancer cell lines in vitro

Abstract

Abstract: Objective To study the specific killing effect of ¹³¹I-labeled Herceptin on breast cancer cell lines positive for Her-2 expression. Methods Anti-Her-2 monoclonal antibody Herceptin was labeled with ¹³¹I by means of IODO-GEN, and the killing effects of Herceptin on SK-BR-3, MCF-7 and A549 cell lines expressing Her-2 were evaluated with MTT assay. Results ¹³¹I-Herceptin had immunoactivity had to that of Herceptin but possessed stronger killing effects on the cell lines expressing Her-2 than Herceptin and ¹³¹I used alone (P<0.05). Its killing effect on cell lines negative or only weakly positive for Her-2 expression was similar to that of ¹³¹I and Herceptin. Conclusion ¹³¹I-Herceptin can specifically kill Her-2-positive cancer cells in vitro.

CLC Number:

R737.9

LIN Jing, LUO Rong-cheng, LI Ai-min, ZHANG Jun-yi, LU Cheng-wei, YAN Xiao. Killing effect of ¹³¹I-Herceptin on breast cancer cell lines in vitro[J]. Journal of Southern Medical University, 2005, 25(06): 663-666.

References

[1] Hayes DF, Thor AD. C-erbB-2 in breast cancer:Development of a clinically useful marker[J]. Semin Oncol, 2002, 29(3):231-45.
[2] Fraker PJ, Speck JR. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1, 3, 4,6-tetrachloro-3a,6adiphrenylglycoluril [J]. Biochem Biophys Res Commun, 1978, 80(4):849-57.
[3] Loosdrecht AA, Nennie E, Ossenkoppele GJ, et al. Cell mediated cytotoxicity against U 937 cells by human monocytes and macrophages in a modified colorimetric MTT assay, A methodological study[J]. J Immunol Methods, 1991, 141(1):15-22.
[4] CarterP, PrestaL, GormanCM, et al. Humanization ofan antip185HER2 antibody for human cancer therapy [J]. Proc Natl Acad Sci USA, 1992, 89(10):4285-9.
[5] Hadded E, Paczesny S, Leblond V, et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 120 patients:a multicenter phase 1-2 clinical trial [J]. Blood, 2001,97(6):1590-97.
[6] vander Kolk LE, Gettitsen W, Baars J, et al. Phage Ⅰ / Ⅱ clinical trial to evaluate the safety of a combination of a chimeric anti-CD20monoclonal antibody and G-CSF given weekly to patienta with relapsed B cell lymphoma [J]. Blood, 1997, 90:512a.
[7] Kimby E, Geisler C, Hagberg H, et al. Rituximab as single agent and in combination with interferon-α as treatment of untreated and first relapse follicular of other low-grade lymphomas [J]. Blood, 2000,96 (Suppl 1):577a.
[8] Denard S J, O’Grady LF, Richman CM, et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody [J].Anticancer Res, 1997, 17(3B):1745-5 1.
[9] Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenograhs[J]. Cancer Res, 1998, 58(13):2825-31.
[10] Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of Her-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers [J]. Oncogene, 1999, 18(13):2241-51.
[11] Pietras RJ, Pegram MD, Finn RS, et al. Remission of human breast cancer xenographs on therapy with humanized monoclonal antibody to Her-2 receptor and DNA-reactive drugs [J]. Oncogene, 1998, 17(17):2235-49.

[1]	LI Xin-an,AN Jing Department of Embryology and Histology,Southern Medical University,Guangzhou 510515,China. Mechanisms of the expression of exogenous genes injected via the mammary duct in rat mammary gland tissue [J]. Journal of Southern Medical University, 2006, 26(12): 1774-.
[2]	WU Wu-jun1,ZENG Jian2,PAN Cheng-en1 1Department of General Surgery,First Hospital of Xi’an Jiaotong University,Xi’an 710061,China;2Department of Gastrointestinal and Glands Surgery,First Affiliated Hospital,Guangxi Medical University,Nanning 530021,China. Efficacy of activated charcoal-epirubicin suspension for treatment of breast cancer with axillary metastasis [J]. Journal of Southern Medical University, 2006, 26(12): 1812-1814.
[3]	KANG Hua-feng,WANG Xi-jing,LIU Xiao-xu,DAI Zhi-jun,XUE Feng-jie,XUE Xing-huan Department of Oncological Surgery,Second Affiliated Hospital,School of Medicine,Xi’an Jiaotong University,Xi’an 710004,China. Chemopreventive effect of celecoxib against DMBA-induced breast cancer and its mechanism [J]. Journal of Southern Medical University, 2006, 26(11): 1599-1602.
[4]	LI Gui-ping1, ZHANG Yi-fan2, WANG Yong-xian3 1Departmant of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; 2Department of Nuclear Medicine, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China; 3Radiopharmaceutical Research Center, Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800, China. 188Re-labeled herceptin inhibits proliferation of breast cancer cell line SKBR-3 in vitro [J]. Journal of Southern Medical University, 2006, 26(10): 1455-1457.
[5]	. [J]. Journal of Southern Medical University, 2006, 26(09): 1378-1379.
[6]	WANG Xiao-yu1, LIN Shao-qiang2, LI Jun-wu2, Kemmner Wolfgang3, DING Yan-qing4 Department of Obstetrics and Gynecology, First Affiliated Hospital of Ji’nan University1, Department of Microbiology and Immunology of Medical College2, Jinan University, Guangzhou 510630, China; 3Max-Delbrueck Center for Molecular Medicine,Berlin 13125, Germany; 4Institute of Oncology, Southern Medical University, Guangzhou 510515, China. Effect of cell surface sialic acid and their linkages on adhesion of mammary carcinoma cells [J]. Journal of Southern Medical University, 2006, 26(06): 742-746.
[7]	WANG Xiao-bing, YANG Qing-xu, PEI Xiao-juan Department of Pathology, Huizhou Central Hospital, Huizhou 516001, China. Expression of angiogenesis-related factors in invasive breast cancer and its clinical significance [J]. Journal of Southern Medical University, 2006, 26(06): 860-863.
[8]	HU Xiao-qu1,QIN Li1,SU Feng-xi1,YAO He-rui2,CHEN Ji-sheng1,GONG Chang1,GUO Ju-jiang1,YU Feng-yan1,JIA Hai-xia1 1Center of Breast Cancer,2Department of Oncology,Second Hospital of Sun Yat-sen University,Guangzhou 510272,China. Vector-mediated HER-2 RNA interference against HER-2-positive breast cancer [J]. Journal of Southern Medical University, 2006, 26(05): 570-572.
[9]	ZHANG Shu-qun1,ZHANG Shu-hui2,XUE Xin-huan1,WANG Xi-jing1,JIANG Jian-tao1 1Department of Oncology,Second Hospital,Xi’an Jiaotong University,Xi’an 710004,China;2Department of Chemical Engineering,Northwestern Polytechnical University,Xi’an 710072,China. Synergism between a siRNA targeted to survivin and 5-FU in inhibiting MCF-7 cell proliferation in vitro [J]. Journal of Southern Medical University, 2006, 26(03): 251-254.
[10]	FAN Yi-xiang,LUO Rong-Cheng,FANG Yong-Xin,YAN Xiao,Department of Oncology,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China. Preparation,quality control and biodistribution of 131I-herceptin in New Zealand rabbits [J]. Journal of Southern Medical University, 2006, 26(03): 361-.
[11]	XU Lei, BAI Zhong-hong, XU Ruan-cheng, YAN Hui, WANG Fang-ju, LUO Rong-cheng Department of Oncology, 91 Hospital of PLA, Jiaozuo 454003, China;Oncology Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Expressions of Her-2, EGFR, PS-2 and ER in breast cancer and their clinical implications [J]. Journal of Southern Medical University, 2006, 26(02): 231-233.
[12]	TAN Ke, FAN Yi-xiang, MIAO Jing-xia, L(?) Cheng-wei, YAN Xiao, LUO Rong-cheng Center of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Killing effect of sequential Herceptin and adriamycin treatment on breast cancer cell line in vitro [J]. Journal of Southern Medical University, 2006, 26(02): 234-236.
[13]	CUI Fei, LUO Rong-cheng, CHEN Jin-zhang, CHEN Bin, HUANG Yu-xian. Therapeutic effect of TAX combined with Herceptin or epirubicin against breast cancer positive for Her-2/neu [J]. Journal of Southern Medical University, 2005, 25(12): 1533-1536.
[14]	LI Rong, ZHENG Hang, LUO Rong-cheng. Cloning and expression of the HER2 gene in MCF-7 cells [J]. Journal of Southern Medical University, 2005, 25(10): 1264-1267.
[15]	ZHENG Hang, LUO Rong-cheng. Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer [J]. Journal of Southern Medical University, 2005, 25(10): 1293-1294,1298.

Killing effect of ¹³¹I-Herceptin on breast cancer cell lines in vitro

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments